Roche wins EU positive opinion for rheumatoid arthritis drug Pharmaceutical Business Review - Nov 25, 2008 RoActemra is said to be the first interleukin-6 receptor-inhibiting monoclonal antibody developed for the treatment of rheumatoid arthritis (RA) and a new ...
New inhibitor drug seen for arthritis, lupus Reuters UK, UK - Nov 24, 2008 ... current commonly-used drugs - methotrexate and anti-CD3," the researchers wrote. Rheumatoid arthritis is an auto-immune disorder with unknown causes. ...
Better Management More Important Than New Drugs for RA MedPage Today, NJ - Nov 26, 2008 26 -- The number of biologic agents for rheumatoid arthritis has increased in recent years, but the best results come from more effective use of available ...
Rheumatoid arthritis drugs too slow to stop damage News-Medical.net, Australia - Nov 10, 2008 ... raises serious questions about the drug Methotrexate which is commonly used to treat rheumatoid arthritis. Rheumatoid arthritis is a chronic autoimmune ...
Source: Google News
Recent News and Articles on the Keywords: arthritis + 15,200 + web Related to the article below (Last Update: 8/7/2008)
Juvenile Arthritis Day at Slugger museum Louisville Courier-Journal, KY - By Ken Neuhauser ? kneuhauser@courier-journal.com ? August 7, 2008 Saturday is Juvenile Arthritis Day -- an event designed to empower children living with ...
Arthritis and the Cancer Connection Cherry Creek News, CO - There is a hopeful spin on the complicated connection between cancer and Rheumatoid Arthritis (RA). According to a recent article inArthritis Today, ...
Doctors Seeing More Arthritis In Active Boomers Boston Channel.com, USA - ?We see a lot more arthritis in Baby Boomers, because they tend to be more active than the past generations,? said John Giurini, a Boston foot and ankle ...
New Remedies Approach Arthritis Pain Gingerly Wall Street Journal - Aug 4, 2008 By LAURA JOHANNES Ginger is delicious in a stir fry, but can it also help arthritis? Ginger in concentrated form is sold as pills, massage oil and now a new ...
Juvenile arthritis needs early detection Indianapolis Star, United States - Aug 4, 2008 Answer: We've changed the name to juvenile idiopathic arthritis. Because it lasts for such a long time, the prevalence is one in 1000. ...
Stroke rehab may be poorer for arthritis patients Reuters UK, UK - Aug 4, 2008 By Michelle Rizzo NEW YORK (Reuters Health) - People with rheumatoid arthritis who suffer a stroke are likely to have lower functional ability subsequently ...
Green tea helps fight arthritis: studies BCLocalNews, Canada - Aug 5, 2008 In one study, researchers took synovial cells from people with rheumatoid arthritis and divided them into two groups, treating one group with a green tea ...
Health: Juvenile Rheumatoid Arthritis CBS 3, PA - Aug 5, 2008 When Caitlin was just three, she was diagnosed with Juvenile Rheumatoid Arthritis. "She has arthritis in all of her joints -- her fingers, toes, elbows, ...
Source: Google News
Structural invariance of constitutively active and inactive mutants of Acanthamoeba myosin IC bound … - BO Carragher, N Cheng, ZY Wang, ED Korn, A Reilein … - Proceedings of the National Academy of Sciences, 1998 - National Acad Sciences ... and Laboratory of Structural Biology, National Institute of Arthritis, Musculoskeletal
and ... directed mutagenesis PNAS, December 22, 1998; 95(26): 15200 - 15205. ...
A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus - A Alejo, MB Ruiz-Arg?ello, Y Ho, VP Smith, M … - Proceedings of the National Academy of Sciences, 2006 - National Acad Sciences ... reactions that cause human diseases such as rheumatoid arthritis (39). ... which is
published as supporting information on the PNAS web site ... USA 101, 15196?15200. ...
[PDF]Catalog# LHB0001 Human - P Buffer, R Kit - tools.invitrogen.com ... and reagents, please visit the BioSource web site at ... Double Discriminator (DD) gate
setting of 7800-15200. ... (2005) Early rheumatoid arthritis is characterized ...
[PDF]Catalog# LMB0001 Mouse - P Buffer, R Kit - biosource.com ... and reagents, please visit the BioSource web site at ... Double Discriminator (DD) gate
setting of 7800-15200. ... (2005) Early Rheumatoid Arthritis is Characterized ...
[PDF]Catalog# LHB0002 P Buffer, R Kit - biosource.com ... For a current listing of available BioSource multiplex bead immunoassays and reagents,
please visit the BioSource web site at www.biosource.com. ...
[BOOK] Jobs and Careers With Nonprofit Organizations: Profitable Opportunities With Nonprofits RL Krannich, CR Krannich - 1998 - Impact Publications
[CITATION] Your Medicare Newsletter E Spring
Smallpox - ZS Moore, JF Seward, JM Lane - The Lancet, 2006 - Elsevier ...Web resources. ... Other complications included corneal ulcer, keratitis, arthritis,
pneumonia, and encephalitis (one in 500 cases of variola major). ...
Archivserver deposit. d-nb. de E B?nffy-J?sika - deposit.ddb.de ... Diese moderne Technologie, die urspr?nglich entwickelt wurde, um die
Informations?bertragung im Web Plattform und System unabh?ngig zu erm?glichen, ...
Source: Google Scholar
Rheumatoid arthritis: Etanercept and Methotrexate combination has demonstrated improvement in physical function and kept joint damage from progressing
Data from a long-term blinded study of anti-TNF agent in patients with rheumatoid arthritis demonstrated that more than three quarters of patients treated with Enbrel ( Etanercept ) plus Methotrexate combination therapy experienced no progression of joint damage at three years.
These new results from the TEMPO ( Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes ) study were presented at the American College of Rheumatology's ( ACR ) Annual Scientific Meeting.
" Rheumatoid arthritis is a chronic condition requiring long-term treatment. It is critical to provide patients with treatment options that not only reduce the signs and symptoms of the disease, but also inhibit the progression of joint damage," said Désirée van der Heijde, at the University of Maastricht in the Netherlands. " The TEMPO results reinforce the benefits of Etanercept and Methotrexate combination therapy and underscore the importance of effective treatment."
At three years, the majority of patients taking Etanercept and Methotrexate combination therapy had no progression of joint damage.
These results were significantly better than those achieved in Etanercept monotherapy and Methotrexate monotherapy-treated patients.
Patients receiving Etanercept monotherapy also had significantly better results than patients receiving Methotrexate monotherapy.
Further, additional data showed that improvement in physical function was higher for the Etanercept combination group than for either therapy alone.
Patients treated with combination therapy experienced a 56 percent mean improvement in Health Assessment Questionnaire ( HAQ ) scores from baseline, compared to 37 percent mean improvement in patients treated with Etanercept alone and 33 percent mean improvement in patients treated with Methotrexate alone.
HAQ scores measure a patient's ability to perform activities of daily living such as dressing, walking, and grooming.
The TEMPO study randomized 686 patients with rheumatoid arthritis , of which 638 were included in the three-year radiographic analysis.
Patients received either Etanercept ( 25 mg twice weekly ), Methotrexate ( up to 20 mg once weekly ), or Etanercept ( 25 mg twice weekly ) plus Methotrexate once weekly.
Patients in the TEMPO trial had active rheumatoid arthritis and an inadequate response to at least one disease-modifying antirheumatic drug ( DMARD ) other than Methotrexate.
The primary radiographic endpoint was the change from baseline in the van der Heijde-modified TSS at one year.
Secondary radiographic endpoints included changes in total erosions, changes in total joint space narrowing, number of eroded joints, and percent of patients with no radiographic progression.
